



Unlock the

**Body's Rhythm**

**PRULAREN**

Prucalopride 1 mg & 2 mg Tablets


# PRULAREN

Prucalopride 1 mg & 2 mg Tablets

## BACKGROUND:


- ➔ Chronic idiopathic constipation (CIC) is the common GI disorder. In general population, the prevalence of constipation worldwide ranges from 0.7 to 79% (median 16%).<sup>1</sup>
- ➔ Prucalopride, a selective serotonin receptor agonist, treats chronic constipation in adults unresponsive to laxatives. It's high selectivity for the 5-HT<sub>4</sub> receptor and potent enterokinetic properties make it more effective than traditional laxatives.<sup>2</sup>

## THERAPEUTIC APPROACH FOR CHRONIC CONSTIPATION<sup>3</sup>



\*Approved by the European Medicine Agency and FDA.

## IMPACT OF PRUCALOPRIDE ON CHRONIC CONSTIPATION SYMPTOMS<sup>3</sup>





# Unlock the Body's Rhythm

## CLINICAL EVIDENCE:

### 1. A PLACEBO-CONTROLLED TRIAL OF PRUCALOPRIDE FOR SEVERE CHRONIC CONSTIPATION.<sup>4</sup>

**Patients:** 620 patients (Prucalopride 2 mg: 207, Prucalopride 4 mg: 204, Placebo: 209)

**Dose:** Prucalopride 2 mg or 4 mg & Placebo

**Duration:** 12 weeks

**Result:** Increase in bowel movements over 12 weeks ( $P < 0.001$ )




Fig. The Primary Efficacy End Point in the Intention-to-Treat Population.

**CONCLUSION:** Over 12 weeks, prucalopride significantly improved bowel function and reduced the severity of symptoms in patients with severe chronic constipation.

### 2. EFFICACY AND SAFETY OF PRUCALOPRIDE IN PATIENTS WITH CHRONIC NONCANCER PAIN SUFFERING FROM OPIOID-INDUCED CONSTIPATION.<sup>5</sup>

**Patients:** 196 patients

**Dose:** Prucalopride 2 mg or 4 mg & Placebo

**Duration:** 4 weeks

**Result:**




Fig. Effect of Prucalopride on the Primary Efficacy End Point

**CONCLUSION:** Prucalopride showed effectiveness in improving bowel movement frequency and reducing symptoms, with a favourable safety profile in patients with opioid-induced constipation.

# PRULAREN

Prucalopride 1 mg & 2 mg Tablets



Unlock the  
Body's Rhythm


## DESCRIPTION:

Prularen-1/2 contains prucalopride and is available as a tablet, in strengths of 1 mg and 2 mg. Prucalopride is a highly selective, high affinity 5-HT<sub>4</sub> receptor agonist that activates both cholinergic and non-adrenergic, non-cholinergic neurotransmission.

## INDICATION:

Indicated in the treatment of chronic idiopathic constipation (CIC).

## MECHANISM OF ACTION:



**Move:** Resulting in increased colonic peristalsis and enhanced bowel motility.

## KEY BENEFITS OF PRUCALOPRIDE:

- ➔ **Superior Efficacy:** Prucalopride is more effective than traditional laxatives in increasing stool frequency and improving consistency.<sup>2,6</sup>
- ➔ **Targeted Action:** It selectively stimulates the 5-HT<sub>4</sub> receptor in the gut, leading to efficient bowel movement stimulation.<sup>2</sup>
- ➔ **Low Interaction Risk:** With minimal protein binding, it poses a lower risk of drug interactions.<sup>6</sup>
- ➔ **Rapid Relief:** Prucalopride achieves peak levels (2-3 hours) quickly after administration, providing fast relief from constipation.<sup>7</sup>

## DOSAGE:

The recommended dose of prucalopride is 2 mg-4 mg once a day or as directed by the physician.

## PRESENTATION:

Prularen 1 mg & 2 mg is available as a strip of 10 tablets.

### References:

1. Approved by the European Medicine Agency and FDA.
2. Aliment Pharmacol Ther 2010; 32: 1113-1123
3. © 2013 The Authors. Neurogastroenterology & Motility published by John Wiley & Sons Ltd. 60 Abbreviations
4. n engl j med 358:22, May 29, 2008
5. Dig Dis Sci (2010) 55:2912-2921
6. <https://doi.org/10.1080/17512433.2019.1620104>
7. Motegrity (prucalopride) Prescribing Information. Lexington, MA: Takeda Pharmaceuticals America, Inc.

## La Renon Healthcare Private Limited

207-208 ISCON Elegance | Circle P | Prahlad Nagar Cross Roads  
S.G.Highway | Ahmedabad - 380015 | Gujarat | India.  
Phone: +91-79-6616-8998 | 2693-6656 | Fax: +91-79-6616-8998  
E-Mail: info@larenon.com | www.larenon.com

I am: \_\_\_\_\_

Call me on: \_\_\_\_\_

Mail me at: \_\_\_\_\_

©2024 All rights reserved, La Renon Healthcare Private Limited